Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 8/2005

01-08-2005

Significant Long-Term Survival After Radiofrequency Ablation of Unresectable Hepatocellular Carcinoma in Patients with Cirrhosis

Authors: Chandrajit P. Raut, MD, Francesco Izzo, MD, Paolo Marra, MD, Lee M. Ellis, MD, Jean-Nicolas Vauthey, MD, Francesco Cremona, MD, Paolo Vallone, MD, Angelo Mastro, MD, Bruno D. Fornage, MD, Steven A. Curley, MD

Published in: Annals of Surgical Oncology | Issue 8/2005

Login to get access

Abstract

Background

Radiofrequency ablation (RFA) offers an alternative treatment in some unresectable hepatocellular carcinoma (HCC) patients with disease confined to the liver. We prospectively evaluated survival rates in patients with early-stage, unresectable HCC treated with RFA.

Methods

All patients with HCC treated with RFA between September 1, 1997, and July 31, 2002, were prospectively evaluated. Patients were treated with RFA by using a percutaneous or open intraoperative approach with ultrasound guidance and were evaluated at regular intervals to determine disease recurrence and survival.

Results

A total of 194 patients (153 men [79%] and 41 women [21%]) with a median age of 66 years (range, 39–86 years) underwent RFA of 289 sonographically detectable HCC tumors. All patients were followed up for at least 12 months (median follow-up, 34.8 months). Percutaneous and open intraoperative RFA was performed in 140 (72%) and 54 (28%) patients, respectively. The median diameter of tumors treated with RFA was 3.3 cm. Disease recurred in 103 (53%) of 194 patients, including 69 (49%) of 140 patients treated percutaneously and 34 (63%) of 54 treated with open RFA (not significant). Local recurrence developed in nine patients (4.6%). Most recurrence was intrahepatic. The overall complication rate was 12%. Overall survival rates at 1, 3, and 5 years for all 194 patients were 84.5%, 68.1%, and 55.4%, respectively.

Conclusions

Treatment with RFA can produce significant long-term survival rates for cirrhotic patients with early-stage, unresectable HCC. RFA can be performed in these patients with relatively low complication rates. Confirmation of these results in randomized trials should be considered.
Literature
1.
Thompson H, Tompkins RK, Longmire WB. Major hepatic resection: a 25-year experience. Ann Surg 1983;197:247–53
2.
Fan ST, Ng IOL, Poon RT, Lo CM, Liu CL, Wong J. Hepatectomy for hepatocellular carcinoma: the surgeon’s role in long-term survival. Arch Surg 1999;134:1124–30
3.
Mazziotti A, Grazi GL, Cavallari A. Surgical treatment of hepatocellular carcinoma in cirrhosis: a Western experience. Hepatogastroenterology 1998;45:1281–7
4.
Nagasue N. Liver resection for hepatocellular carcinoma: indications, techniques, complications, and prognostic factors. J Hepatobiliary Pancreat Surg 1998;5:7–13
5.
Watkins KT, Curley SA. Liver, bile ducts. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE, (eds.) Clinical Oncology. New York: Churchill Livingstone, 2000:1681–748
6.
Rossi S, Fornari F, Paties C, Buscarini L. Thermal lesions induced by 480-KHz localized current field in guinea pig and in pig livers. Tumori 1990;76:54–7
7.
Sanchez H, van Sonnenberg E, D’Agostine H. Percutaneous tissue ablation by radiofrequency thermal energy as a preliminary to tumor ablation. Minim Invasive Ther 1993;2:299–305
8.
McGahan JP, Browning PD, Brock JM, Tesluk H. Hepatic ablation using radiofrequency electrocautery. Invest Radiol 1990;25:267–70
9.
Lounsberry W, Goldschmidt V, Linke C. The early histologic changes following electrocoagulation. Gastrointest Endosc 1995;41:68–70
10.
Ahmad SA, Bilimoria MM, Wang X, et al. Hepatitis B or C virus serology as a prognostic factor in patients with hepatocellular carcinoma. J Gastrointest Surg 2001;5:468–76
11.
Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693–9
12.
Fong Y, Sun RL, Jarnagin W, Blumgart LH. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg 1999;229:790–800
13.
Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 2000;32:1224–9
14.
Livraghi T, Bolondi L, Buscarini L, et al. No treatment, resection and ethanol injection in hepatocellular carcinoma: a retrospective analysis of survival in 391 patients with cirrhosis. Italian Cooperative HCC Study Group. J Hepatol 1995;22:522–6
15.
Curley SA, Izzo F, Ellis LM, Nicolas Vauthey J, Vallone P. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg 2000;232:381–91
16.
Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–81
17.
Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999;19:271–85
18.
Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8–29
19.
Bismuth H, Majno PE, Adam R. Liver transplantation for hepatocellular carcinoma. Semin Liver Dis 1999;19:311–22
20.
Poon RT, Fan ST, Lo CM, et al. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg 2001;234:63–70
21.
Oka H, Kurioka N, Kim K, et al. Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology 1990;12:680–7
22.
Chang CH, Chau GY, Lui WY, Tsay SH, King KL, Wu CW. Long-term results of hepatic resection for hepatocellular carcinoma originating from the noncirrhotic liver. Arch Surg 2004;139:320–5
23.
Giovannini M, Moutardier V, Danisi C, Bories E, Pesenti C, Delpero JR. Treatment of hepatocellular carcinoma using percutaneous radiofrequency thermoablation: results and outcomes in 56 patients. J Gastrointest Surg 2003;7:791–6
24.
Cha C, Fong Y, Jarnagin WR, Blumgart LH, DeMatteo RP. Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J Am Coll Surg 2003;197:753–8
25.
Poon RT, Ng KK, Lam CM, Ai V, Yuen J, Fan ST. Effectiveness of radiofrequency ablation for hepatocellular carcinomas larger than 3 cm in diameter. Arch Surg 2004;139:281–7
26.
Bilchik AJ, Wood TF, Allegra D, et al. Cryosurgical ablation and radiofrequency ablation for unresectable hepatic malignant neoplasms: a proposed algorithm. Arch Surg 2000;135:657–62; discussion 662–4
27.
Rossi S, Garbagnati F, Lencioni R, et al. Percutaneous radiofrequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply. Radiology 2000;217:119–26
28.
Harrison LE, Koneru B, Baramipour P, et al. Locoregional recurrences are frequent after radiofrequency ablation for hepatocellular carcinoma. J Am Coll Surg 2003;197:759–64
29.
Pawlik TM, Izzo F, Cohen DS, Morris JS, Curley SA. Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients. Ann Surg Oncol 2003;10:1059–69
30.
Scaife CL, Curley SA. Complication, local recurrence, and survival rates after radiofrequency ablation for hepatic malignancies. Surg Oncol Clin North Am 2003;12:243–55
Metadata
Title
Significant Long-Term Survival After Radiofrequency Ablation of Unresectable Hepatocellular Carcinoma in Patients with Cirrhosis
Authors
Chandrajit P. Raut, MD
Francesco Izzo, MD
Paolo Marra, MD
Lee M. Ellis, MD
Jean-Nicolas Vauthey, MD
Francesco Cremona, MD
Paolo Vallone, MD
Angelo Mastro, MD
Bruno D. Fornage, MD
Steven A. Curley, MD
Publication date
01-08-2005
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 8/2005
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/ASO.2005.06.011

Other articles of this Issue 8/2005

Annals of Surgical Oncology 8/2005 Go to the issue

OriginalPaper

Efficacy of Repeat Isolated Limb Perfusions With Tumor Necrosis Factor α and Melphalan for Multiple In-Transit Metastases in Patients with Prior Isolated Limb Perfusion Failure

Editorial

What Is the Best Treatment for Stage IV Colorectal Cancer?

OriginalPaper

Surgical Resection of Primary Tumors in Patients Who Present With Stage IV Colorectal Cancer: An Analysis of Surveillance, Epidemiology, and End Results Data, 1988 to 2000

Editorial

Preoperative Multimodality Treatment of Localized Soft Tissue Sarcoma: Addition Through Subtraction?

OriginalPaper

Predicting Biopsy Outcome After Mammography: What Is the Likelihood the Patient Has Invasive or In Situ Breast Cancer?

OriginalPaper

Preoperative Chemoradiotherapy (Modified Eilber Protocol) Provides Maximum Local Control and Minimal Morbidity in Patients With Soft Tissue Sarcoma